Clearance in Primary Ciliary Dyskinesia (CLIP)
Evaluating Non-ciliary Mechanisms of Airway Clearance in Muco-obstructive Lung Disease
Understanding mechanisms of mucus clearance from the airways may lead to treatments in muco-obstructive lung conditions. Mucociliary clearance (MCC) scans are a way to measure the rate at which a person's lungs can clear inhaled particles. Through a single-arm pilot study in participants with primary ciliary dyskinesia (PCD), the investigators will evaluate the effect of exercise as a way to increase clearance through a mechanism called gas liquid transport (GLT) where the faster flow of air through the lungs during exercise is able to clear more particles. The investigators will repeat MCC measures with exercise after administering hypertonic saline (HS) to evaluate the effects of mucus hydration on both GLT and cough clearance (CC).
Aim 1. To quantify non-ciliary, non-cough mechanisms of mucus clearance (i.e., GLT) in PCD through an MCC protocol that introduces a standardized exercise intervention after isotope delivery.
Aim 2. To evaluate whether exercise-induced GLT and/or CC are responsive to hydrator intervention, using a short acting bronchodilator with 7% HS prior to isotope delivery followed by MCC with exercise intervention.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The investigators will perform an open label, single-arm interventional pilot study with all participants undergoing the interventions (exercise, and exercise with HS pretreatment) and serving as their own control to evaluate the effects of exercise on non-ciliary mucus clearance mechanisms in PCD to better identify role of GLT and CC. The investigators will also evaluate the effect of pretreatment with HS on GLT (if present) and CC, to determine if these mechanisms of mucus clearance are modifiable by future therapies in PCD and other muco-obstructive lung diseases.
Patients will be asked to attend a total of 3 study visits: screening visit 1 (V1), baseline exercise MCC (visit 2 (V2) or visit 3 (V3)), and HS pretreatment MCC (V2 or V3). Patients will be randomized to perform their baseline exercise MCC scan first or their HS pretreatment MCC scan first to minimize introduction of bias. The time between V1 and V2 will be 3 days to 28 days to allow for flexibility of scheduling, but participants already prescribed HS will be required to undergo a washout period of at least 3 days. V3 will take place at least 3 days after V2 to allow for remaining MCC isotope washout. At V1, tolerability and change in airway caliber in response to HS will be assessed by symptom assessment and spirometry, along with the performance of an exercise assessment to inform the exercise protocol in V2 and V3. From the baseline exercise MCC visit, the primary outcome of Whole Lung Total GLT will be measured. Through comparing the data from the exercise MCC visit and the HS pretreatment MCC visit, change in Whole Lung Total GLT and CC will be determined.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前：Katherine A Despotes, MD
- 電話番号：919-966-1055
- メール：katherine.despotes@unchealth.unc.edu
研究連絡先のバックアップ
- 名前：Corinne Taylor
- メール：corinne.lawler@unc.edu
研究場所
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27278
- University of North Carolina at Chapel Hill
-
コンタクト：
- Katherine A Despotes, MD
- 電話番号：919-966-1055
- メール：katherine.despotes@unchealth.unc.edu
-
コンタクト：
- Corinne Taylor
- メール：corinne.lawler@unc.edu
-
主任研究者：
- Katherine A Despotes, MD
-
-
参加基準
適格基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- 18 years old or older
- Diagnosis of PCD with supporting genetics
- Lung function with forced expiratory volume in 1 second (FEV1) percent predicted >30%
- Ability to exercise for 20 minutes (Exercise Assessment performed at screening visit)
Exclusion Criteria:
- Intolerance to 7% HS
- Failure of HS tolerance test (HSTT) at visit 1 (V1), defined as a decline of 10% in FEV1 from baseline pre-bronchodilator (BD) FEV1 after 7% HS
- Intolerance to levalbuterol
- Exercise-induced asthma
- Complex congenital heart disease or other exercise limitation
- Lung transplantation or listed for lung transplantation
- History of lung resection of the lung analyzed by MCC (depending on situs status)
- Pregnancy or unwillingness to use approved birth control during study period
- Recent hemoptysis (>60 ml in the last 3 months)
- Pulmonary exacerbation in preceding 4 weeks
- Change in pulmonary therapies within preceding 4 weeks
- Resting or exertional O2 requirement (nocturnal acceptable)
- Tobacco / smoking history (any within last year, and >10 pack year history in past)
- More than 2 chest computed tomography (CT) scans in the past year or a combination of procedures believed to have exposed the lungs to >150 millisieverts (mSv), including from other research studies
- Participation in another interventional trial within 30 days
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的：Exercise with and without HS pretreatment
All participants will undergo interventions of exercise alone, and exercise with HS pretreatment, in two separate study visits according to randomization to intervention sequence.
|
At either V2 or V3, after 16 minutes of baseline MCC data collection, participants will perform 20 minutes of moderate-intensity exercise based on the Borg Rating of Perceived Exertion (RPE) scale, on a cycle ergometer.
The goal through this moderate intensity exercise is to increase respiratory rate and airflow velocity, thereby potentially inducing GLT.
Participants will then resume MCC scan data collection post-exercise to continue to measure the effects induced by exercise on clearance from the lungs.
At either V2 or V3, prior to the start of baseline MCC scanning, participants will undergo pretreatment with 4 puffs of inhaled levalbuterol (90 mcg per actuation, via spacer) followed by 4 ml of 7% HS via nebulizer.
Participants will then start MCC scan data collection, and after 16 minutes of baseline MCC collection they will then complete 20 minutes of moderate intensity exercise according to the Borg RPE on a cycle ergometer.
After 20 minutes, MCC scan will resume to continue to measure rates of clearance following HS pretreatment and exercise.
|
この研究は何を測定していますか？
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Whole Lung Total GLT
時間枠：Either Day 1 (Visit 2) or up to Day 28 (Visit 3) depending on randomization to sequence intervention
|
Through MCC scan with built in exercise protocol, the investigators will measure the effects of exercise on rates of clearance of radiolabeled isotopes from the lungs, thought to represent GLT.
The investigators will measure the difference between retained particles from immediately before (after collection of 16 minutes of baseline MCC data through eight 2-minute images) and immediately after 20 minutes of moderate intensity exercise on a cycle ergometer (40 minutes after start of MCC data collection).
This will represent Active GLT.
The investigators will then resume measurement of MCC clearance rate by serial 2-minute image collection of the whole lung from 40 minutes to 70 minutes.
This will represent Sustained GLT.
The sum of Active and Sustained GLT will represent Whole Lung GLT.
This measurement will occur at either Visit 2 or Visit 3, depending on visit sequence randomization.
|
Either Day 1 (Visit 2) or up to Day 28 (Visit 3) depending on randomization to sequence intervention
|
|
Change in Whole Lung Total GLT after HS pretreatment
時間枠：Day 3 to 28, depending on timing of Visit 3
|
After pretreatment with levalbuterol and 7% HS, participants will undergo an MCC scan with built in exercise protocol.
The investigators will measure the effects of exercise on rates of clearance of radiolabeled isotopes from the lungs, thought to represent GLT.
The investigators will measure Active GLT and Sustained GLT after HS pretreatment, which taken together will represent Whole Lung GLT after HS pretreatment.
This measurement will occur at either Visit 2 or Visit 3 depending on visit sequence randomization.
The difference between Whole Lung GLT from exercise alone will be compared with the HS pretreatment Whole Lung GLT.
|
Day 3 to 28, depending on timing of Visit 3
|
|
Change in Cough Clearance (CC) after HS Pretreatment
時間枠：Day 3 to 28, depending on timing of Visit 3
|
The investigators will measure the effects of exercise and HS pretreatment on rates of clearance of radiolabeled isotopes from the lungs during a period of controlled coughs at regular intervals.
During Visit 2 and Visit 3 MCC scans, from minutes 70 through 100 of MCC data collection, participants will be instructed to perform 30 voluntary huff-cough maneuvers while serial 2-minute images are obtained.
The change in clearance during this time will represent CC.
At one of these visits (either Visit 2 or Visit 3 depending on randomization to intervention sequence), participants will undergo pretreatment with levalbuterol and 7% HS prior to the MCC scan with exercise protocol.
The difference between CC after exercise alone and CC after exercise with HS pretreatment will be measured.
|
Day 3 to 28, depending on timing of Visit 3
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者：Katherine A Despotes, MD、University of North Carolina, Chapel Hill
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 25-1650
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。